Vilanterol

證據等級: L5

預測適應症: 10 個

Vilanterol: Data-Gap-Driven Confirmation of Obstructive Lung Disease (COPD/Asthma) Use

One-Sentence Summary

This evidence pack shows no recorded original indication or mechanism of action for Vilanterol — both are flagged as data gaps in the source database, and the drug is not currently marketed in Taiwan. The TxGNN model's top prediction is Obstructive Lung Disease, and the supporting evidence — 80+ clinical trials (many completed Phase 3) and 20 publications, including the landmark IMPACT and FULFIL trials — shows this is not a novel repurposing signal but Vilanterol's already well-established, globally approved role as a long-acting β2-agonist (LABA) in COPD/asthma combination inhalers (e.g., Breo/Relvar Ellipta, Anoro Ellipta, Trelegy Ellipta). This case should be read as data-gap remediation and confirmation, not discovery of a new indication.

Quick Overview

Item	Content
Original Indication	Not available — no approved indication on file (drug not marketed in Taiwan; original_indications field empty in source data)
Predicted New Indication	Obstructive Lung Disease (COPD / Asthma)
TxGNN Prediction Score	99.97%
Evidence Level	L1 (≥2 completed Phase 3 RCTs)
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

The evidence pack's structured original_moa field is a data gap, but the underlying trial and literature evidence consistently describes Vilanterol's pharmacology: it is a selective long-acting β2-adrenergic receptor agonist (LABA) that activates β2 receptors on bronchial smooth muscle, increasing intracellular cAMP and producing sustained bronchodilation (~24-hour duration). This is a direct, mechanism-based pharmacological effect on airway obstruction — not a speculative network-inferred association.

Critically, "obstructive lung disease" is not a new therapeutic direction for Vilanterol — it is the drug's core, already-marketed indication internationally, delivered as a component of fixed-dose combination inhalers with fluticasone furoate (Breo/Relvar Ellipta), umeclidinium (Anoro Ellipta), or both (Trelegy Ellipta, triple ICS/LAMA/LABA therapy). The empty original_indications and original_moa: [Data Gap] fields in this evidence pack should be understood as a database population gap, not evidence that the drug lacks an established indication.

Because the mechanism-to-disease link is direct rather than inferred, and because the evidence base includes large, high-quality confirmatory trials (e.g., the 10,355-patient IMPACT trial and the FULFIL trial), this candidate scores at the highest evidence tier (L1) despite the underlying data gaps in the drug-level metadata.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02164513	Phase 3	Completed	10,355	IMPACT trial — FF/UMEC/VI triple therapy reduces annual exacerbation rate vs. FF/VI or UMEC/VI dual therapy in COPD
NCT01706198	Phase 3	Completed	4,233	12-month effectiveness of FF/VI once-daily vs. usual asthma maintenance therapy
NCT01313650	Phase 3	Completed	1,538	Pivotal 24-week efficacy/safety study of UMEC/VI and individual components vs. placebo in COPD
NCT02467452	Phase 3	Completed	1,479	Non-inferiority of triple pMDI therapy vs. FF/VI plus tiotropium in COPD
NCT02729051	Phase 3	Completed	1,055	Closed triple therapy (FF/UMEC/VI) vs. open triple (FF/VI + UMEC) — lung function comparison in COPD
NCT03248128	Phase 3	Completed	906	FF/VI vs. FF alone in pediatric/adolescent asthma (5–17y) uncontrolled on ICS
NCT01822899	Phase 3	Completed	717	UMEC/VI vs. fluticasone/salmeterol over 12 weeks in COPD (Grade A relevance)
NCT01817764	Phase 3	Completed	707	UMEC/VI vs. fluticasone/salmeterol over 12 weeks in COPD (Grade A relevance)
NCT05757102	Phase 3	Recruiting	292	FF/UMEC/VI vs. FF/VI in adolescents (12–17y) with inadequately controlled asthma; Bayesian dynamic borrowing design
NCT03378648	Phase 1/2	Completed	118	First-in-human safety/PK/PD study of a bifunctional muscarinic antagonist/β2-agonist (MABA) bronchodilator compound

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29668352	2018	RCT	NEJM	IMPACT trial — triple ICS/LAMA/LABA therapy vs. dual therapy in COPD
32162970	2020	RCT (mortality analysis)	Am J Respir Crit Care Med	FF/UMEC/VI significantly reduces all-cause mortality vs. UMEC/VI in COPD
28375647	2017	RCT	Am J Respir Crit Care Med	FULFIL trial — once-daily triple therapy superior to ICS/LABA dual therapy in COPD
32918892	2021	RCT (Phase 3A)	Lancet Respir Med	CAPTAIN trial — FF/UMEC/VI vs. FF/VI in inadequately controlled asthma
32299860	2020	RCT subgroup analysis	Eur Respir J	IMPACT trial — effect of exacerbation history on treatment outcomes
35849317	2022	Network meta-analysis	Adv Ther	FF/UMEC/VI vs. other COPD therapies — comparative efficacy
39696097	2024	Systematic review & meta-analysis	BMC Pulm Med	UMEC/VI vs. other bronchodilators in COPD management
31389190	2019	Systematic review	Clin Respir J	Fixed-dose UMEC/VI combination for COPD — systematic review
30463451	2018	Review	Expert Rev Respir Med	FF/UMEC/VI combination therapy for COPD
28956463	2017	Review	Expert Rev Respir Med	Fluticasone furoate and vilanterol for COPD treatment

Taiwan Market Information

No authorizations on file. Vilanterol-containing products are not currently marketed in Taiwan according to this evidence pack (total_licenses: 0, licenses: []).

Safety Considerations

Please refer to the package insert for safety information. This evidence pack contains no key warnings, contraindications, or drug interaction data (all flagged as data gaps; DDI query returned no results), and this is recorded as a Blocking data gap (DG001) preventing formal safety pre-assessment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The link between Vilanterol and obstructive lung disease is supported by L1-level evidence — multiple completed Phase 3 RCTs including the large-scale IMPACT and FULFIL trials — and reflects a direct, established pharmacological mechanism (LABA bronchodilation) rather than a speculative prediction. However, this evidence pack's drug-level metadata (original indication, MOA) and all safety/regulatory data (TFDA label, contraindications, DDI) are missing, and the drug is not currently marketed in Taiwan, so it cannot yet proceed past initial safety screening (S1/S3 gate).

To proceed, the following is needed:

Resolve DG001 (Blocking): retrieve TFDA label warnings/contraindications, or confirm via original manufacturer labeling (Breo/Anoro/Trelegy Ellipta) if Vilanterol is imported as a combination product
Resolve DG002 (High): populate MOA and original indication fields from DrugBank to correct the apparent "data gap" that is driving this candidate to appear as a novel prediction rather than a confirmed existing use
Confirm Taiwan regulatory/import status for Vilanterol-containing combination products
Reclassify this candidate internally as data confirmation, not new indication discovery, to avoid misrepresenting an already-approved global indication as a repurposing finding

Note on other predicted indications (ranks 2–10): the remaining candidates in this evidence pack (hyperlucent lung, interstitial emphysema, compensatory emphysema, tracheal stenosis, tracheal calcification, laryngotracheitis, congenital lobar emphysema, bronchial neoplasm, respiratory malformation) are either pure TxGNN model scores with no supporting clinical trial or literature evidence (L5, Hold), or show evidence/topic mismatches where the underlying trials and papers are generic COPD/asthma studies unrelated to the specific predicted disease (likely ontology label mismatch). None of these are ready for further evaluation without additional targeted evidence.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.